Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against JN.1 Subvariants in Adult Participants

Amparo L. Figueroa,[1] Bethany Girard,[1] Darin K Edwards,[1] Arshan Nasir,[1] Kimball Johnson,[2] Steven Hack,[1] Xin Cao,[1] Elizabeth de Windt,[1] Veronica Urdaneta,[1] Frances Priddy,[1] Rituparna Das,[1] David C Montefiori,[3] Spyros Chalkias[1]

[1]Moderna, Inc., Cambridge, Massachusetts 02142, USA; [2]CenExel, Decatur, Georgia 30030, USA; [3]Duke University Medical Center, Durham, North Carolina 27710, USA.

Running title: Evaluation of JN.1 and KP.2 Vaccines

Corresponding author:

Amparo L. Figueroa

Moderna, Inc., 325 Binney Street, Cambridge, MA, USA 02142

Phone: 1-617-335-3762

amparo.figueroa@modernatx.com

Keywords: immunogenicity, SARS-CoV-2, KP.2 vaccine, JN.1 vaccine, mRNA-1273

Abstract

In this ongoing, open-label phase 3b/4 study, JN.1- and KP.2-encoding monovalent mRNA-1273 vaccines elicited robust neutralizing antibody responses against vaccine-matched variants and cross-neutralized currently circulating JN.1 subvariants (KP.3.1.1, XEC, LP.8.1) in adults with previous COVID-19 mRNA vaccination, with reduced cross-neutralization observed against all subvariants tested. No safety concerns were identified.

Background

Rapid spread and diversification of the SARS-CoV-2 Omicron lineage led to the JN.1 variant, which became globally dominant by early 2024 [1] and continues to diversify, with KP.2 having circulated previously, and KP.3.1.1, XEC, and LP.8.1 currently circulating worldwide [2]. XEC, a recombination-derived lineage [3, 4] has acquired 2 new mutations (T22N, F59S), compared with the previously dominant KP.3 [3, 5]. Recently, XEC is increasingly outcompeted by LP.8.1, a KP.1.1.3 subvariant containing 9 new spike mutations versus JN.1 [4, 5] and 6 versus KP.2 [2]. LP.8.1 is increasingly prevalent globally, having become dominant in the United States [4, 6]. While LP.8.1 seems to be no more immune-evasive than XEC, it shows enhanced spike-hACE2 engagement, likely facilitating its gradual replacement over XEC [5]. Due to increasing global prevalence, both have been classified as variants under monitoring by the World Health Organization [2], accounting for 76% of sequenced variants (LP.8.1: 70%; XEC: 6%) in the US as of May 2025 [6].

Antigenic evolution within the JN.1 lineage led to authorization of monovalent JN.1- and KP.2-encoding mRNA COVID-19 vaccines (2024-2025 formula) [7, 8]. Preclinical versions of these vaccines evaluated in naive (2-dose primary series) and previously immunized mice (booster) were shown to neutralize vaccine-matched variants and cross-neutralize JN.1 subvariants KP.2, KP.3, LA.2, and XEC (XEC in naïve mice only) [9], supporting variant selection and updated vaccine approvals. The JN.1- and KP.2-encoding mRNA-1273 vaccines are expected to remain cross-reactive to emerging JN.1 lineage variants [4, 9]; however, clinical data on potential cross-neutralization are not yet available.

This study was conducted as part of an ongoing trial (NCT06585241) aiming to generate human serology data to assess immunogenicity and cross-neutralization

of updated variant formulations of mRNA-1273 as new SARS-CoV-2 variants emerge. We evaluated the immunogenicity and cross-neutralization of the JN.1-encoding vaccine (mRNA-1273.167) and the KP.2-encoding vaccine (mRNA-1273.712) against vaccine-matched variants and currently circulating variants (KP.3.1.1, XEC, LP.8.1) [2, 6] in adults with previous COVID-19 mRNA vaccination; safety was also evaluated.

Methods

Study Design and Participants

This is an ongoing, open-label, single-arm, phase 3b/4 study evaluating immunogenicity and safety of monovalent formulations of mRNA-1273 encoding the SARS-CoV-2 Omicron variants JN.1 (mRNA-1273.167) and KP.2 (mRNA-1273.712). Eligible participants were US adults (≥18 years) with ≥3 previous mRNA COVID-19 vaccinations (≥2 mRNA COVID-19 vaccines and an XBB.1.5-encoding mRNA COVID-19 vaccine received between September 2023-August 2024). Participants received a 0.5-mL dose of a single intramuscular injection (50 µg) of either mRNA-1273.167 (Subprotocol 1) or mRNA-1273.712 (Subprotocol 2) and were followed for 1 month. Adults with known history of SARS-CoV-2 infection within 3 months before enrollment were excluded (**Supplementary Appendix**). The study is being conducted in accordance with the Declaration of Helsinki and Council for International Organizations of Medical Sciences international ethical guidelines, International Council for Harmonisation good clinical practice guidelines, and applicable laws and regulations.

Patient Consent Statement

Protocol, informed consent form, and other relevant documents were reviewed and approved by the institutional review board/independent ethics

committee (Advarra, Columbia, MD, USA) before study initiation. Informed consent was obtained prior to enrollment into the study.

Study Vaccines

mRNA-1273.167 (Spikevax, Moderna, Inc.) contains 50 µg of mRNA encoding the full-length SARS-CoV-2 spike protein of the JN.1 variant with 2 proline residue substitutions to stabilize the spike protein into a prefusion conformation. mRNA-1273.712 contains 50 µg of mRNA encoding the prefusion-stabilized spike protein of the KP.2 variant.

Immunogenicity and Safety Assessments

Sera for assessments of neutralizing antibody (nAb) responses were collected before vaccine administration (Day 1) and 4 weeks after immunization (Day 29). The nAb titers were quantified using a lentivirus-based SARS-CoV-2 pseudovirus neutralization assay (Duke University), described previously [10]. Safety assessments included adverse events (AEs) leading to study withdrawal, serious AEs (SAEs), and AEs of special interest (AESIs) from Day 1 through the end of the study.

Statistical Analysis

Immunogenicity was evaluated in the per-protocol immunogenicity set (PPIS), comprising all participants who received a planned study vaccine, had a negative reverse transcriptase polymerase chain reaction (RT-PCR) test at Days 1 and 29, and no major protocol deviations impacting the key data. The primary endpoint was geometric mean (GM) titer and GM fold rise (GMFR) of nAb at Day 29 relative to baseline, with corresponding 95% confidence intervals. Safety was assessed in the safety set (all enrolled participants who received study intervention). No statistical

hypothesis testing was performed; a descriptive summary of the primary immunogenicity objective was provided.

Results

Overall, 50 participants were independently enrolled in each subprotocol and received mRNA-1273.167 (Subprotocol 1; median age, 63 years; 62% female; 86% Black/African American) or mRNA-1273.712 (Subprotocol 2; median age, 54 years; 66% female; 70% Black/African American). Median time on study was 30 days (mRNA-1273.167 cohort) and 29 days (mRNA-1273.712 cohort). Prior COVID-19 vaccination was categorized into 2, 3, 4, and ≥5 doses, with 76-80% of participants having received 3 doses across subprotocols (median time [interquartile range, IQR] since last dose: mRNA-1273.167, 310 days [303-316]; mRNA-1273.712, 330 days [277-338]). Prior COVID-19 vaccination included an original mRNA monovalent formulation (mRNA-1273 or BNT162b2: 100% recipients [mRNA-1273.167]; 96% recipients [mRNA-1273.712]), and Omicron bivalent formulation (mRNA-1273 or BNT162b2: 100% recipients [both subprotocols]). Baseline SARS-CoV-2 status was determined by virologic (RT-PCR) and/or serologic (anti-nucleocapsid binding antibody) evidence of SARS-CoV-2 infection on/before Day 1. No participants reported a known SARS-CoV-2 infection within the past 3 months. In Subprotocol 1, 39 (78.0%) participants were SARS-CoV-2 positive at baseline; PPIS included 48 (96.0%) participants (two were excluded due to a missing or positive SARS CoV-2 RT-PCR result on Day 29). In Subprotocol 2, 43 (86.0%) participants were baseline SARS-CoV-2 positive; PPIS included 49 (98.0%) participants (one was excluded due to a positive or missing SARS CoV-2 RT-PCR result on Day 29).

Both JN.1-encoding (mRNA-1273.167) and KP.2-encoding (mRNA-1273.712) vaccines elicited robust increases in nAb responses at Day 29 relative to baseline

against matched variants (GMFR, 11.6-11.7) and cross-neutralized JN.1-lineage subvariants not matched to the vaccine (GMFR, mRNA-1273.167: KP.2, 8.1; KP.3.1.1, 10.5; XEC, 12.9; LP.8.1, 10.8; GMFR, mRNA-1273.712: JN.1, 10.8; KP.3.1.1, 12.4; XEC, 12.1; LP.8.1, 14.3; **Figure 1**). The highest titers were measured against JN.1 for both vaccines (GMT: mRNA-1273.167, 1670.0; mRNA-1273.712, 2796.4). Relative to the JN.1 reference, a reduction in cross-neutralization was observed against JN.1-lineage subvariants (KP.3.1.1, XEC, LP.8.1) for both vaccines, with the greatest reduction measured against KP.3.1.1 (**Figure 2**). Higher nAb responses were elicited by mRNA-1273.712 than mRNA-1273.167 against all tested variants (**Figure 2**).

No SAEs, deaths, or AEs leading to study withdrawal were reported throughout the study. One AESI (pulmonary embolism) was reported in the study, which was considered unrelated to vaccination by the investigator. At 23 days post-vaccination in the JN.1 cohort, a participant in their 50s with hypothyroidism presented to the emergency department with chest pain/diaphoresis; a small pulmonary embolism was found, and the participant was treated with anticoagulants and then discharged on oral anticoagulants.

Discussion

In this phase 3b/4 study evaluating adults with previous COVID-19 mRNA vaccination, monovalent JN.1- and KP.2-encoding mRNA-1273 vaccines (mRNA-1273.167, mRNA-1273.712) induced robust nAb responses against matched variants and cross-neutralized newly-emerged JN.1 subvariants (KP.3.1.1, XEC, LP.8.1). Cross-neutralization was reduced across all subvariants versus JN.1. No safety concerns were identified over the 1-month follow-up period. While both vaccines induced cross-neutralization consistent with the expected potent cross-

153 reactivity of the JN.1- and KP.2-encoding vaccines against emerging JN.1-lineage
154 subvariants [4, 9], decreased cross-neutralization measured against KP.3.1.1, XEC,
155 and LP.8.1 for both vaccines suggested that recently emerged variants have
156 developed some immune escape from responses induced by currently approved
157 COVID-19 vaccine compositions. At Day 29, the KP.2-encoding vaccine (mRNA-
158 1273.712) induced higher nAb responses than the JN.1-encoding vaccine (mRNA-
159 1273.167) against all variants tested, suggesting an advantage in preventing escape.
160 The highest reduction in cross-neutralization was observed for KP.3.1.1, consistent
161 with data reporting increased resistance to serum neutralization of KP.3.1.1 versus
162 XEC in KP.2 vaccine recipients [11]. The drop in cross-neutralization versus the JN.1
163 reference ranged between 1.5 and 3.4 after the JN.1- and KP.2-encoding vaccines,
164 which was lower than that reported against JN.1 (~5.8-fold reduction) after booster
165 vaccination with the XBB.1.5-encoding mRNA-1273 vaccine authorized for the 2023-
166 2024 season [10]. These data are consistent with the reported cross-neutralization of
167 KP.2 monovalent boosters against JN.1 subvariants, including KP.3.1.1 and XEC,
168 and with observations of reduced neutralization against these subvariants versus
169 JN.1 or KP.2 [12, 13]. Similar findings were reported for the JN.1-encoding mRNA
170 booster among healthcare workers, with the highest neutralization measured against
171 JN.1, and 1.9- and 2.9-fold lower titers measured against KP.3.1.1 and XEC,
172 respectively [14].
173 Study limitations include small sample size and lack of durability assessments
174 of nAb responses. Higher baseline titers in the KP.2 cohort might have influenced
175 higher nAb titers and fold-rises at Day 29, although greater fold-rises for KP.2,
176 KP.3.1.1, and LP.8.1 were observed in the KP.2 cohort despite higher baseline titers.

177 Participant enrollment in the JN.1 and KP.2 vaccine arms was non-randomized, and
178 comparisons should be made cautiously.
179 In conclusion, the JN.1- and KP.2-encoding monovalent mRNA-1273 vaccines
180 elicited robust nAb responses against matched variants and cross-neutralized
181 currently circulating JN.1 subvariants (KP.3.1.1, XEC, LP.8.1), with reduced cross-
182 neutralization observed against all subvariants tested. No safety concerns were
183 identified.

Funding

The work was supported by Moderna, Inc.

Acknowledgments

Medical writing and editorial assistance were provided by Anja Varjačić, PhD, of MEDiSTRAVA in accordance with Good Publication Practice (GPP 2022) guidelines, funded by Moderna, Inc., and under the direction of the authors. These data were previously presented at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global), April 11-15, 2025, Vienna, Austria.

Author contributions

A.L.F., B.G., D.K.E., A.N., S.H., X.C., E.d.W., V.U., F.P., R.D., and S.C. conceived and planned the study. A.L.F., B.G., A.N., K.J., S.H., E.d.W., V.U., R.D., and D.C.M. collected the data. A.L.F., B.G., D.K.E., A.N., S.H., X.C., E.d.W., V.U., R.D., D.C.M., and S.C. contributed to data analysis and interpretation. All authors contributed to drafting of the manuscript and contributed to the critical revision of the manuscript for important intellectual content. All authors met the authorship criteria and approved the publication.

Potential conflicts of interest

A.L. F., B.G., D.K.E., A.N., S.H., X.C., E.D.W., V.U., F.P., R.D., and S.C., are employees of Moderna, Inc., and may hold stock/stock options in the company. K.J. is an employee of CenExel and holds stock in the company. D.C.M. reports laboratory funding from Moderna, Inc.

206 **Data availability statement**

207 As the trial is ongoing, access to patient-level data presented in the article and
208 supporting clinical documents by qualified external researchers who provide
209 methodologically sound scientific proposals may be available upon reasonable
210 request for products or indications that have been approved by regulators in the
211 relevant markets and subject to review from 24 months after study completion. Such
212 requests can be made to Moderna, Inc., 325 Binney Street, Cambridge, MA, 02142
213 USA << data_sharing@modernatx.com>>. A materials transfer and/or data access
214 agreement with the sponsor will be required for accessing shared data. All other
215 relevant data are presented in the paper.

216

References

1. World Health Organization. Updated Risk Evaluation of JN.1 09 February 2024. Available at: https://cdn.who.int/media/docs/default-source/documents/health-topics/sars/jn.1-9-february-2024.pdf. Accessed December 12 2024.

2. World Health Organization. WHO COVID-19 dashboard. Available at: https://data.who.int/dashboards/covid19/variants. Accessed May 19 2025.

3. Kaku Y, Okumura K, Kawakubo S, et al. Virological characteristics of the SARS-CoV-2 XEC variant. Lancet Infect Dis **2024**; 24:e736.

4. World Health Organization. Initial Risk Evaluation of LP.8.1 03 February 2025. Available at: https://www.who.int/publications/m/item/risk-evaluation-for-sars-cov-2-variant-under-monitoring-lp81. Accessed March 4 2025.

5. Liu J, Yu Y, Yang S, et al. Virological and antigenic characteristics of SARS-CoV-2 variants LF.7.2.1, NP.1, and LP.8.1. Lancet Infect Dis **2025**; 25:e128-30.

6. Centers for Disease Control and Prevention. COVID Data Tracker. Available at: https://covid.cdc.gov/covid-data-tracker/#variant-summary. Accessed May 19 2025.

7. World Health Organization. Statement on the Antigen Composition of COVID-19 Vaccines. Available at: https://www.who.int/news/item/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines. Accessed March 4 2025.

8. Food and Drug Administration. FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently. Accessed March 4 2025.

240 9. Lee DW, Nasir A, Elbashir S, et al. mRNA-1273 vaccines adapted to JN.1 or KP.2
241 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in
242 mice. Vaccine **2025**; 54:126961.
243 10. Chalkias S, McGhee N, Whatley JL, et al. Interim Report of the Reactogenicity
244 and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-
245 Containing Vaccines. J Infect Dis **2024**; 230:e279-86.
246 11. Wang Q, Guo Y, Mellis IA, et al. Antibody evasiveness of SARS-CoV-2
247 subvariants KP.3.1.1 and XEC. bioRxiv **2024**:2024.11.17.624037.
248 12. Suthar MS, Manning KE, Ellis ML, et al. The KP.2-adapted COVID-19 vaccine
249 improves neutralising activity against the XEC variant. Lancet Infect Dis **2025**;
250 25:e122-3.
251 13. Wang Q, Mellis IA, Wu M, et al. KP.2-based monovalent mRNA vaccines robustly
252 boost antibody responses to SARS-CoV-2. Lancet Infect Dis **2025**; 25:e133-4.
253 14. Arora P, Happle C, Kempf A, et al. Impact of JN.1 booster vaccination on
254 neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC. Lancet Infect Dis **2024**;
255 24:e732-3.
256
257

258 **Figure Legends**

259

260 **Figure 1**. Neutralizing antibody responses (GMT and GMFR) elicited by mRNA-
261 1273.167 (JN.1-encoding vaccine) and mRNA-1273.712 (KP.2-encoding vaccine)
262 against the vaccine-matched variants (JN.1, KP.2) and newly emerged subvariants
263 (KP.3.1.1, XEC, LP.8.1), per-protocol immunogenicity set.
264 The GMT (Day 1 and Day 29) with the corresponding GMFR (Day 29 relative to Day
265 1) are shown. The per-protocol immunogenicity set included participants who
266 received the planned study intervention, had negative RT-PCR tests at baseline (Day
267 1) and Day 29, and had no major protocol deviations that impacted the key data. The
268 boundary of boxes represents the 25th (bottom) and 75th (top) percentiles of the
269 GMT. The solid line inside the box represents the median (50th percentile) of the
270 GMT. The dashed line inside the box represents the GMT. Whiskers (vertical lines)
271 represent the lowest and highest data points within 1.5 of the interquartile range.
272 The LLOQ is presented using a grey dashed line. The LOD is presented using a
273 brown dashed line.
274 Abbreviations: GMFR, geometric mean fold rise; GMT, geometric mean titer;
275 ID_{50}, 50% inhibitory dilution; LLOQ, lower limit of quantification; LOD, limit of
276 detection; RT-PCR, reverse transcription polymerase chain reaction.

277

278

279 **Figure 2**. Geometric mean fold-drop in variant-specific neutralizing antibody
280 responses at Day 29 after mRNA-1273.167 (JN.1-encoding vaccine) and mRNA-
281 1273.712 (KP.2-encoding vaccine), per-protocol immunogenicity set.
282 The LLOQ is presented using a grey dashed line. The LOD is presented using a
283 brown dashed line.
284 Annotated fold change indicates fold-drop compared with the reference variant JN.1.
285 Abbreviations: LLOQ, lower limit of quantification; LOD, limit of detection.
286

287 **Figure Alt Text**

288 **Figure 1**: Graphs showing neutralizing antibody responses against vaccine-matched
289 variants and newly emerged variants at baseline and Day 29 after JN.1- and KP.2-
290 encoding mRNA-1273.712 vaccines, illustrated with boxplots and individual data
291 points.

292 **Figure 2**: Graphs comparing geometric mean fold-drop in variant-specific
293 neutralizing antibody responses at Day 29 after JN.1- and KP.2-encoding mRNA-
294 1273.712 vaccines, illustrated with bars and individual data points.

295

296 **Figures**

297 **Figure 1**. Neutralizing antibody responses elicited by mRNA-1273.167 (JN.1

298 vaccine) and mRNA-1273.712 (KP.2 vaccine) against the vaccine-matched variants

299 (JN.1, KP.2) and newly emerged variants (KP.3.1.1, XEC, LP.8.1), per-protocol

300 immunogenicity set.



301

302 **Figure 2**. Geometric mean fold-drop in variant-specific neutralizing antibody responses at Day 29 after mRNA-1273.167 (JN.1

303 vaccine) and mRNA-1273.712 (KP.2 vaccine), per-protocol immunogenicity set.



304